Table 2.

Average ASCVD Risk and ASCVD Risk Reductions Due to Improvements in the ABCS

AverageImprovement in clinical outcomes
ASCVDAll ABCSAspirin OnlyBlood Pressure OnlyCholesterol OnlySmoking Only
Baseline10.1110.1110.1110.1110.11
All practices
Post-intervention10.0310.1010.0810.0810.10
Absolute change (p-value)−0.08 (P < .001)−0.01 (P > .05)−0.03 (P > .05)−0.03 (P > .05)−0.01 (P > .05)
Relative change−0.79−0.14−0.30−0.28−0.07
Practices with median or higher improvement
Post-intervention9.7910.069.9310.0410.09
Absolute change−0.32 (P < .001)−0.05 (P > .05)−0.18 (P > .05)−0.08 (P > .05)−0.02 (P > .05)
Relative change−3.28−0.53−1.79−0.75−0.20
  • Notes: The table shows estimated average ASCVD risk in the EvidenceNOW patient population at baseline and post-intervention as well as the absolute and relative change in ASCVD risk for five scenarios: improvement in all ABCS; improvement only in aspirin prescribing; improvement only in blood pressure control; improvement only in cholesterol monitoring; and improvement only in smoking intervention. Results for absolute changes also include bootstrapped p-values in parenthesis. Baseline ASCVD risks are identical for all interventions displayed in the table because they are all based on the full study sample. Baseline levels of ABCS were as follows: 61.9 (aspirin prescribing); 63.3 (blood pressure control); 60.2 (cholesterol management); 58.4 (smoking intervention). Changes in ABCS (if assumed for a scenario) for all practices were: 3.4 (aspirin prescribing); 1.6 (blood pressure control); 4.4 (cholesterol management); 7.4 (smoking intervention). Changes in ABCS (if assumed for a scenario) for practices with median or higher improvements were: 12.9 (aspirin prescribing); 9.4 (blood pressure control); 12.0 (cholesterol management); 20.1 (smoking intervention).

    Abbreviation: ASCVD = atherosclerotic cardiovascular disease.